Atovaquone/Proguanil Supply Update for Providers: 2026

As a prescriber, you've likely fielded calls from patients who can't find Atovaquone/Proguanil at their pharmacy. While the medication is not in formal shortage, localized availability issues are common — and your patients look to you for solutions. This guide covers the current supply landscape, clinical alternatives, and practical strategies for keeping your patients protected.

Current Supply Status

As of March 2026, Atovaquone/Proguanil is not listed on the FDA Drug Shortages Database. The medication continues to be produced by multiple generic manufacturers, including Mylan (Viatris), Teva, Cipla, Sun Pharma, Aurobindo, Lupin, and Glenmark. Brand-name Malarone (GSK) also remains available.

The availability issues patients are experiencing are primarily driven by:

• Seasonal demand surges — Prescriptions spike during summer, winter holidays, and spring break travel seasons
• Retail pharmacy stocking patterns — Just-in-time inventory means many pharmacies don't carry Atovaquone/Proguanil on the shelf
• Geographic variability — Pharmacies in areas with high international travel volume tend to stock it more reliably than those in other areas

Clinical Considerations for Prescribers

Generic Substitution

All FDA-approved generic formulations of Atovaquone/Proguanil are bioequivalent. If you're writing for brand Malarone, consider prescribing generically (Atovaquone/Proguanil 250/100 mg) to give pharmacies maximum flexibility in sourcing from available manufacturers. This can significantly improve fill rates and reduce cost for patients ($43-$70 generic with coupon vs. $200-$350 for Malarone).

Prescribing Adequate Lead Time

Encourage patients to seek prescriptions 4-6 weeks before travel. This allows time for:

• Travel medicine consultation and any required vaccinations
• Pharmacy ordering if not in stock (1-3 business days typical)
• Insurance prior authorization if needed
• Switching to an alternative if availability is an issue

Alternative Antimalarial Agents

When Atovaquone/Proguanil is unavailable or contraindicated, the following alternatives are recommended per CDC guidelines:

Doxycycline

• Dosing: 100 mg PO daily, starting 1-2 days before exposure, continuing 4 weeks post-exposure
• Advantages: Widely available, inexpensive ($10-$30/course), effective in all malaria regions, additional coverage for rickettsial diseases and leptospirosis
• Limitations: Photosensitivity, GI intolerance, esophageal ulceration risk, vaginal candidiasis, contraindicated in pregnancy and children under 8, longer post-travel course (4 weeks vs. 7 days)
• Clinical pearl: Recommend enteric-coated formulation and taking with food/water to minimize GI side effects. Advise aggressive sun protection.

Mefloquine

• Dosing: 250 mg PO weekly, starting ≥2 weeks before exposure, continuing 4 weeks post-exposure
• Advantages: Weekly dosing improves adherence on long trips, effective in most regions, can be used in 2nd/3rd trimester pregnancy
• Limitations: FDA boxed warning for neuropsychiatric effects (anxiety, depression, psychosis, seizures). Contraindicated with psychiatric history, seizure disorders, cardiac conduction abnormalities. Screen carefully before prescribing.
• Clinical pearl: Start 2-3 weeks early to assess tolerability before departure. If neuropsychiatric symptoms emerge, discontinue and switch.

Chloroquine

• Dosing: 500 mg (300 mg base) PO weekly, starting 1-2 weeks before exposure, continuing 4 weeks post-exposure
• Limitations: Only appropriate for chloroquine-sensitive P. falciparum areas (limited: parts of Central America, Caribbean, Middle East). Check CDC country-specific guidance.

Tafenoquine (Arakoda)

• Dosing: 200 mg PO daily x3 days (loading), then 200 mg weekly during exposure, then 200 mg x1 post-exposure
• Advantages: Weekly dosing with shorter post-travel course
• Limitations: Requires quantitative G6PD testing (contraindicated in G6PD deficiency due to hemolytic anemia risk). Not approved for children under 18 or pregnant/lactating women. High cost ($500-$700+). Limited pharmacy stocking.

Patient Communication Strategies

When patients call about difficulty filling Atovaquone/Proguanil:

1. Reassure them — This is a stocking issue, not a shortage. The medication exists and can be obtained.
2. Direct them to stock-finding tools — Recommend MedFinder to check pharmacy stock in real time. GoodRx and SingleCare also show availability alongside pricing.
3. Offer to transfer the prescription — Send the Rx electronically to a pharmacy that has it in stock.
4. Discuss alternatives proactively — Before the patient leaves your office, mention that if Atovaquone/Proguanil is unavailable, Doxycycline is a widely available backup. Consider writing a contingency prescription.
5. Help with cost — Remind patients that generic Atovaquone/Proguanil with a GoodRx or SingleCare coupon costs ~$43-$70 for 30 tablets. Travel prophylaxis may not be covered by all insurance plans.

Prescribing Tips to Improve Fill Rates

• Prescribe generically — Write for "Atovaquone/Proguanil" rather than "Malarone" to allow any manufacturer's product
• Include DAW 0 — Allow substitution explicitly
• Specify the indication — "Malaria prophylaxis for travel" helps pharmacists understand urgency and may prompt faster ordering
• Consider e-prescribing to a large chain — CVS, Walgreens, Walmart, and Costco pharmacies have better wholesale access
• Leverage your EHR — If your system supports preferred pharmacy selection, direct to pharmacies known to stock antimalarials

Resources for Providers

• CDC Malaria Prophylaxis Guidelines: cdc.gov/malaria/hcp/drug-malaria
• FDA Drug Shortages Database: accessdata.fda.gov/scripts/drugshortages
• MedFinder for Providers: medfinder.com/providers — Help your patients find medications in stock
• CDC Yellow Book: Country-specific malaria prophylaxis recommendations

For a patient-facing version of this update, see our Atovaquone/Proguanil shortage update for patients. For guidance on helping patients save money, read our provider's guide to patient savings.